Medical cannabis: A forward vision for the clinician
Open Access
- 29 January 2018
- journal article
- review article
- Published by Wiley in European journal of pain
- Vol. 22 (3) , 485-491
Abstract
Medical cannabis has entered mainstream medicine and is here to stay. Propelled by public advocacy, the media and mostly anecdote rather than sound scientific study, patients worldwide are exploring marijuana use for a vast array of medical conditions including management of chronic pain. Contrary to the usual path of drug approval, medical cannabis has bypassed traditional evidence‐based study and has been legalized as a therapeutic product by legislative bodies in various countries. While there is a wealth of basic science and preclinical studies demonstrating effects of cannabinoids in neurobiological systems, especially those pertaining to pain and inflammation, clinical study remains limited. Cannabinoids may hold promise for relief of symptoms in a vast array of conditions, but with many questions as yet unanswered. Rigorous study is needed to examine the true evidence for benefits and risks for various conditions and in various patient populations, the specific molecular effects, ideal methods of administration, and interaction with other medications and substances. In the context of prevalent use, there is an urgency to gather pertinent clinical information about the therapeutic effects as well as risks. Even with considerable uncertainties, the health care community must adhere to the guiding principle of clinical care ‘primum non nocere’ and continue to provide empathetic patient care while exercising prudence and caution. The health care community must strongly advocate for sound scientific evidence regarding cannabis as a therapy.Significance: Legalization of medical cannabis has bypassed usual drug regulatory procedures in jurisdictions worldwide. Pending sound evidence for effect in many conditions, physicians must continue to provide competent empathetic care with attention to harm reduction. A vision to navigate the current challenges of medical cannabis is outlined.Keywords
This publication has 47 references indexed in Scilit:
- Marijuana use and risk of lung cancer: a 40-year cohort studyCancer Causes & Control, 2013
- Persistent cannabis users show neuropsychological decline from childhood to midlifeProceedings of the National Academy of Sciences, 2012
- Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosisArthritis & Rheumatism, 2010
- The Prevalence and Significance of Cannabis Use in Patients Prescribed Chronic Opioid Therapy: A Review of the Extant LiteraturePain Medicine, 2009
- Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritisArthritis Research & Therapy, 2008
- Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis2008
- Cannabinoid‐mediated antinociception is enhanced in rat osteoarthritic kneesArthritis & Rheumatism, 2007
- Targeting cannabinoid agonists for inflammatory and neuropathic painExpert Opinion on Investigational Drugs, 2007
- A short guide to the nomenclature of seven-transmembrane spanning receptors for lipid mediatorsLife Sciences, 2005
- The cannabinomimetic arachidonyl‐2‐chloroethylamide (ACEA) acts on capsaicin‐sensitive TRPV1 receptors but not cannabinoid receptors in rat jointsBritish Journal of Pharmacology, 2004